Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease / Zhang, Huai; Targher, Giovanni; Byrne, Christopher D; Kim, Seung Up; Wong, Vincent Wai-Sun; Valenti, Luca; Glickman, Myer; Ponce, Jaime; Mantzoros, Christos S; Crespo, Javier; Gronbaek, Henning; Yang, Wah; Eslam, Mohammed; Wong, Robert J; Machado, Mariana Verdelho; Yu, Ming-Lung; Ghanem, Omar M; Okanoue, Takeshi; Liu, Jun-Feng; Lee, Yong-Ho; Xu, Xiao-Yuan; Pan, Qiuwei; Sui, Meili; Lonardo, Amedeo; Yilmaz, Yusuf; Zhu, Li-Yong; Moreno, Christophe; Miele, Luca; Lupsor-Platon, Monica; Zhao, Lei; Lamasters, Teresa LeAnn; Gish, Robert G; Zhang, Huijie; Nedelcu, Marius; Chan, Wah Kheong; Xia, Ming-Feng; Bril, Fernando; Shi, Jun-Ping; Datz, Christian; Romeo, Stefano; Sun, Jian; Liu, Dan; Sookoian, Silvia; Mao, Yi-Min; Méndez-Sánchez, Nahum; Wang, Xiao-Yan; Pyrsopoulos, Nikolaos T; Fan, Jian-Gao; Fouad, Yasser; Sun, Dan-Qin; Giannini, Cosimo; Chai, Jin; Xia, Ze-Feng; Jun, Dae Won; Li, Guo-Jing; Treeprasertsuk, Sombat; Li, Ying-Xu; Cheung, Tan To; Zhang, Faming; Goh, George Boon-Bee; Furuhashi, Masato; Seto, Wai-Kay; Huang, Hui; Di Sessa, Anna; Li, Qing-Hong; Cholongitas, Evangelos; Zhang, Le; Silveira, Themis Reverbel; Sebastiani, Giada; Adams, Leon A; Chen, Wei; Qi, Xiaolong; Rankovic, Ivan; De Ledinghen, Victor; Lv, Wen-Jie; Hamaguchi, Masahide; Kassir, Radwan; Müller-Wieland, Dirk; Romero-Gomez, Manuel; Xu, Ying; Xu, Yi-Cong; Chen, Shi-Yao; Kermansaravi, Mohammad; Kuchay, Mohammad Shafi; Lefere, Sander; Parmar, Chetan; Lip, Gregory Y H; Liu, Chun-Jen; Åberg, Fredrik; Lau, George; George, Jacob; Sarin, Shiv Kumar; Zhou, Jing-Ya; Zheng, Ming-Hua; Pastori, Daniele. - In: HEPATOLOGY INTERNATIONAL. - ISSN 1936-0533. - 18:4(2024), pp. 1178-1201. [10.1007/s12072-024-10702-5]

A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Miele, Luca;Romeo, Stefano;Chen, Wei;Pastori, Daniele
2024

Abstract

Background: With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11. Methods: Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members. Results: A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%). Conclusions: This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.
2024
global survey; ICD-11; MAFLD
01 Pubblicazione su rivista::01a Articolo in rivista
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease / Zhang, Huai; Targher, Giovanni; Byrne, Christopher D; Kim, Seung Up; Wong, Vincent Wai-Sun; Valenti, Luca; Glickman, Myer; Ponce, Jaime; Mantzoros, Christos S; Crespo, Javier; Gronbaek, Henning; Yang, Wah; Eslam, Mohammed; Wong, Robert J; Machado, Mariana Verdelho; Yu, Ming-Lung; Ghanem, Omar M; Okanoue, Takeshi; Liu, Jun-Feng; Lee, Yong-Ho; Xu, Xiao-Yuan; Pan, Qiuwei; Sui, Meili; Lonardo, Amedeo; Yilmaz, Yusuf; Zhu, Li-Yong; Moreno, Christophe; Miele, Luca; Lupsor-Platon, Monica; Zhao, Lei; Lamasters, Teresa LeAnn; Gish, Robert G; Zhang, Huijie; Nedelcu, Marius; Chan, Wah Kheong; Xia, Ming-Feng; Bril, Fernando; Shi, Jun-Ping; Datz, Christian; Romeo, Stefano; Sun, Jian; Liu, Dan; Sookoian, Silvia; Mao, Yi-Min; Méndez-Sánchez, Nahum; Wang, Xiao-Yan; Pyrsopoulos, Nikolaos T; Fan, Jian-Gao; Fouad, Yasser; Sun, Dan-Qin; Giannini, Cosimo; Chai, Jin; Xia, Ze-Feng; Jun, Dae Won; Li, Guo-Jing; Treeprasertsuk, Sombat; Li, Ying-Xu; Cheung, Tan To; Zhang, Faming; Goh, George Boon-Bee; Furuhashi, Masato; Seto, Wai-Kay; Huang, Hui; Di Sessa, Anna; Li, Qing-Hong; Cholongitas, Evangelos; Zhang, Le; Silveira, Themis Reverbel; Sebastiani, Giada; Adams, Leon A; Chen, Wei; Qi, Xiaolong; Rankovic, Ivan; De Ledinghen, Victor; Lv, Wen-Jie; Hamaguchi, Masahide; Kassir, Radwan; Müller-Wieland, Dirk; Romero-Gomez, Manuel; Xu, Ying; Xu, Yi-Cong; Chen, Shi-Yao; Kermansaravi, Mohammad; Kuchay, Mohammad Shafi; Lefere, Sander; Parmar, Chetan; Lip, Gregory Y H; Liu, Chun-Jen; Åberg, Fredrik; Lau, George; George, Jacob; Sarin, Shiv Kumar; Zhou, Jing-Ya; Zheng, Ming-Hua; Pastori, Daniele. - In: HEPATOLOGY INTERNATIONAL. - ISSN 1936-0533. - 18:4(2024), pp. 1178-1201. [10.1007/s12072-024-10702-5]
File allegati a questo prodotto
File Dimensione Formato  
Zhang_Global_2024.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1728820
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact